Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy



Anti-Cancer Agents in Medicinal Chemistry, 5(2): 107-113.

Author(s): K. Jin Yoon, Philip M. Potter and Mary K Danks.

Affiliation: Department of Molecular Pharmacology, St. Jude Children's Research Hospital.

Abstract

Anticancer enzyme / prodrug approaches to therapy are designed to activate prodrugs specifically at tumor loci, to achieve antitumor responses with minimal toxicity. The equivocal success of these approaches thus far has led to searches for more efficient combinations. This mini-review evaluates and compares characteristics of seven selected enzyme / prodrug combinations, and discusses goals for future development of effective combinations.

Keywords:

enzyme prodrug therapy, hsv-tk gcv, Herves Simplex Virus-Thymidine Kinase Ganciclovir, cd 5-fc, cytosine deaminase 5-fluorocytosine, pnpase 2-f-araa, purine nucleoside phosphorylase 2-fluoroarabinosyl adenine.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 5
Issue Number: 2
First Page: 107
Last Page: 113
Page Count: 7
DOI: 10.2174/1568011053174837
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science